SynthesisOral and maxillofacial surgery2026
The role of elective neck dissection in parotid acinic cell carcinoma: a systematic review.
Synthesis in Oral and maxillofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcinic cell carcinoma (AciCC) is a rare parotid malignancy treated by parotidectomy with or without a neck dissection depending on clinical or radiographic neck node involvement. The role of elective neck dissection (END) in the clinically node-negative neck, intended to address occult lymph node metastases (OLNM), remains contentious.
methodsThis review was conducted per PRISMA 2020. Searches through PubMed, EMBASE, and CINAHL were conducted up to May 2025. Data extraction focused on survival, recurrence outcomes and OLNM. Risk of bias was assessed using the Newcastle-Ottawa Scale.
resultsFrom 741 screened articles, 13 retrospective cohort studies were included. Across 2,646 parotid AciCC cases, 788 underwent END, 77 demonstrating OLNM. Marked heterogeneity was observed among studies, with reported OLNM rates ranging from 0% to 37.5% and a weighted mean of 9.8%. High-grade transformation was associated with poorer survival; advanced T-stage showed a less consistent association, and grade-stratified nodal differences were generally based on small samples and not statistically significant.
conclusionRoutine END is not supported in low-grade, early-stage AciCC. High-grade transformation is an adverse prognostic factor; the independent value of advanced T-stage is less certain, resting largely on some single cohort studies. END has not been shown to improve survival, and comparisons are confounded by indication. Any role in higher-risk disease remains uncertain and should be individualised rather than routine. Multi-institutional registries with standardised reporting are needed to strengthen the evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.